ConductScience.org, home

Paper2953239

Vasodilators and regression of left ventricular hypertrophy. Hydralazine versus prazosin in hypertensive humans.

Leenen FH and 4 others. Am J Med, 1987. Cited by 121 papers, by iCite.

Cite this record

ConductScience Library. Vasodilators and regression of left ventricular hypertrophy. Hydralazine versus prazosin in hypertensive humans. Papers, record 2953239. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2953239

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Vasodilators and regression of left ventricular hypertrophy. Hydralazine versus prazosin in hypertensive humans.
PubMed
Journal
Am J Med
PubMed
Year
1987
PubMed
Publication types
Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
121
iCite
Relative citation ratio, by iCite
6.04
iCite
Revised in PubMed
2019-06-26
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Leenen FHF H
2Smith DLD L
3Farkas RMR M
4Reeves RAR A
5Marquez-Julio AA

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CardiomegalyMajor topic
HydralazineMajor topic
HypertensionMajor topic
PrazosinMajor topic
Vasodilator AgentsMajor topic
Adult
Female
Humans
Male
Middle Aged

Source PubMed

Download CSV of topics

Cited by15

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 121 citations.

PMIDTitleJournalYearIn PapersSource
39680249Diagnosis of Primary Aldosteronism without Discontinuation of Interfering Antihypertensive Medications.Curr Hypertens Rep2024https://conductscience.org/library/papers/39680249PubMed
34515895The Effects of Verapamil, Hydralazine, and Doxazosin on Renin, Aldosterone, and the Ratio Thereof.Cardiovasc Drugs Ther2023https://conductscience.org/library/papers/34515895PubMed
34054559The Effect of Antihypertensive Medications on Testing for Primary Aldosteronism.Front Pharmacol2021https://conductscience.org/library/papers/34054559PubMed
24790136Rap1b in smooth muscle and endothelium is required for maintenance of vascular tone and normal blood pressure.Arterioscler Thromb Vasc Biol2014https://conductscience.org/library/papers/24790136PubMed
20136844Vasodilator therapy with hydralazine induces angiotensin AT receptor-mediated cardiomyocyte growth in mice lacking guanylyl cyclase-A.Br J Pharmacol2010https://conductscience.org/library/papers/20136844PubMed
8762091Action of the calcium channel blocker lacidipine on cardiac hypertrophy and endothelin-1 gene expression in stroke-prone hypertensive rats.Br J Pharmacol1996https://conductscience.org/library/papers/8762091PubMed
3254831Effects of long term treatment with pinacidil and nifedipine on left ventricular anatomy and function in patients with mild to moderate systemic hypertension.Drugs1988https://conductscience.org/library/papers/3254831PubMed
3191000Topical minoxidil: cardiac effects in bald man.Br J Clin Pharmacol1988https://conductscience.org/library/papers/3191000PubMed
2535100Left ventricular mass changes with nicardipine therapy in essential hypertension.Cardiovasc Drugs Ther1989https://conductscience.org/library/papers/2535100PubMed
2149513Left ventricular hypertrophy reversal with labetalol and propranolol: a prospective randomized, double-blind study.Cardiovasc Drugs Ther1990https://conductscience.org/library/papers/2149513PubMed
1981020Effects of nifedipine versus hydralazine on sympathetic activity and cardiac function in patients with hypertension persisting on diuretic plus beta-blocker therapy.Cardiovasc Drugs Ther1990https://conductscience.org/library/papers/1981020PubMed
1724641Regression of increased left ventricular mass by antihypertensives.Drugs1991https://conductscience.org/library/papers/1724641PubMed
1687998Selective alpha 1-adrenoreceptor blockers in the treatment of hypertension: should we be using them more?Clin Auton Res1991https://conductscience.org/library/papers/1687998PubMed
1390327Regression of left ventricular hypertrophy in "previously untreated" hypertensive blacks after 6 months of blood pressure reduction with alpha- and beta-adrenergic blockade and thiazide therapy.Cardiovasc Drugs Ther1992https://conductscience.org/library/papers/1390327PubMed
1290920
A comparison of the effects of the selective peripheral alpha 1-blocker terazosin with the selective beta 1-blocker atenolol on blood pressure, exercise performance and the lipid profile in mild-to-moderate essential hypertension.
Clin Auton Res1992https://conductscience.org/library/papers/1290920PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
BCL2A1597PubTator's text mininghttps://conductscience.org/library/genes/597NCBI Gene
REN5972PubTator's text mininghttps://conductscience.org/library/genes/5972NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/2953239

GET https://conductscience.org/api/papers/v1/2953239/authors